Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Peter L. Turecek, PhD, Juergen Siekmann, PhD, Artur Mitterer, PhD, Michael Graninger, PhD, Gerald Schrenk, PhD, Peter Matthiessen, PhD, Hanspeter Rottensteiner, PhD, Werner Hoellriegl, DVM, Marietta Putz, MS, Hans Peter Schwarz, MD, Friedrich Scheiflinger, PhD

Blood (2015) 126 (23): 3536.

https://doi.org/10.1182/blood.V126.23.3536.3536

Published: 2015

Journal Articles

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients

Shawn F. J. Whelan, Christoph J. Hofbauer, Frank M. Horling, Peter Allacher, Martin J. Wolfsegger, Johannes Oldenburg, Christoph Male, Jerzy Windyga, Andreas Tiede, Hans Peter Schwarz, Friedrich Scheiflinger, Birgit M. Reipert

Blood (2013) 121 (6): 1039–1048.

https://doi.org/10.1182/blood-2012-07-444877

Published: 2013

Includes: Supplemental data

Journal Articles

Preclinical Safety of Baxter's Recombinant ADAMTS13

Christina Piskernik, DVM, Barbara Dietrich, DVM, Susan Kubik, BSc, Tanja Ruthsatz, DVM, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch, DVM

Blood (2012) 120 (21): 3381.

https://doi.org/10.1182/blood.V120.21.3381.3381

Published: 2012

Journal Articles

Preclinical Efficacy Testing of Baxter's Recombinant ADAMTS13 in a Mouse Model of TTP.

Alexandra Schiviz, DVM, Marlene Resch, DVM, Elisa Farnleitner, Hanspeter Rottensteiner, PhD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Werner Hoellriegl, PhD, Eva-Maria Muchitsch, DVM

Blood (2012) 120 (21): 2216.

https://doi.org/10.1182/blood.V120.21.2216.2216

Published: 2012

Journal Articles

Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.

Wilfried Auer, PhD, Hanspeter Rottensteiner, PhD, Gerald Schrenk, PhD, Werner Hoellriegl, PhD, Alexandra Schiviz, DVM, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Peter L Turecek, PhD, Eva-Maria Muchitsch, PhD

Blood (2012) 120 (21): 2233.

https://doi.org/10.1182/blood.V120.21.2233.2233

Published: 2012

Journal Articles

A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13

Alexandra Schiviz, Kuno Wuersch, Christina Piskernik, Barbara Dietrich, Werner Hoellriegl, Hanspeter Rottensteiner, Friedrich Scheiflinger, Hans Peter Schwarz, Eva-Maria Muchitsch

Blood (2012) 119 (25): 6128–6135.

https://doi.org/10.1182/blood-2011-09-380535

Published: 2012

Includes: Supplemental data

Journal Articles

CD4 + T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice

Katharina N. Steinitz, Pauline M. van Helden, Brigitte Binder, David C. Wraith, Sabine Unterthurner, Corinna Hermann, Maria Schuster, Rafi U. Ahmad, Markus Weiller, Christian Lubich, Maurus de la Rosa, Hans Peter Schwarz, Birgit M. Reipert

Blood (2012) 119 (17): 4073–4082.

https://doi.org/10.1182/blood-2011-08-374645

Published: 2012

Includes: Supplemental data

Journal Articles

Preclinical Immunogenicity Assessment of Baxter‘s Longer-Acting FVIII Candidate BAX 855 Using Novel Preclinical Models,

Frank M Horling, PhD, Sandra Schwele, PhD, Christian Lubich, Rafi U Ahmad, PhD, Markus Weiller, PhD, Margit Spatzenegger, Hans Peter Schwarz, MD, Birgit M Reipert, PhD

Blood (2011) 118 (21): 3323.

https://doi.org/10.1182/blood.V118.21.3323.3323

Published: 2011

Journal Articles

Preclinical Immunogenicity Assessment of Baxter‘s Recombinant Factor VIIa,

Frank M Horling, PhD, Christine Lenk, Rafi Uddin Ahmad, PhD, Markus Weiller, PhD, Maria Schuster, DVM, Hans Peter Schwarz, MD, Birgit M Reipert, PhD

Blood (2011) 118 (21): 3327.

https://doi.org/10.1182/blood.V118.21.3327.3327

Published: 2011

Journal Articles

Deciphering of CD4 + T Cell Subsets Involved in Maintenance and Break of Immune Tolerance in a Humanized Mouse Model That Is Immune Tolerant to Human FVII

Christine Lenk, Markus Pasztorek, Markus Weiller, PhD, Rafi Uddin Ahmad, PhD, Hans Peter Schwarz, MD, Friedrich Scheiflinger, PhD, Birgit M Reipert, PhD, Maurus de la Rosa, PhD

Blood (2011) 118 (21): 2188.

https://doi.org/10.1182/blood.V118.21.2188.2188

Published: 2011

Journal Articles

Induction and Break of Immune Tolerance to Human FVIII in a HLA-DRB1*1501 Humanized Hemophilic Mouse Model

Katharina Nora Steinitz, PhD, Brigitte Binder, Christian Lubich, Rafi Uddin Ahmad, PhD, Markus Weiller, PhD, Maurus de la Rosa, PhD, Hans Peter Schwarz, MD, Friedrich Scheiflinger, PhD, Birgit M Reipert, PhD

Blood (2011) 118 (21): 2280.

https://doi.org/10.1182/blood.V118.21.2280.2280

Published: 2011

Journal Articles

Safety of Baxter’s Longer Acting rFVIII (BAX 855) After Repeated Application in Rats and Cynomolgus Monkeys

Barbara Dietrich, DVM, Margit Spatzenegger, PhD, Reinhard Stidl, PhD, Martin Wolfsegger, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4345.

https://doi.org/10.1182/blood.V118.21.4345.4345

Published: 2011

Journal Articles

Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys

Gerald Hoebarth, DVM, Susan Kubik, BSc, Martin Wolfsegger, PhD, John-Philip Lawo, Alfred Weber, PhD, Herbert Gritsch, Werner Hoellriegl, Alexandra Schiviz, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4346.

https://doi.org/10.1182/blood.V118.21.4346.4346

Published: 2011

Journal Articles

Efficacy of Baxter’s Longer Acting rFVIII (BAX 855) in Mouse Models of Hemophilia A

Alexandra Schiviz, Eder Barbara, John-Philip Lawo, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Peter L Turecek, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch, Werner Hoellriegl

Blood (2011) 118 (21): 4350.

https://doi.org/10.1182/blood.V118.21.4350.4350

Published: 2011

Journal Articles

Preclinical Safety Pharmacology of Baxter’s Longer Acting rFVIII (BAX 855)

Barbara Dietrich, DVM, Susan Kubik, BSc, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4357.

https://doi.org/10.1182/blood.V118.21.4357.4357

Published: 2011

Journal Articles

Absorption, Metabolism, Distribution, and Excretion of Longer Acting rFVIII (BAX 855) Following Intravenous Administration to Rats

Reinhard Stidl, PhD, Juergen Siekmann, PhD, Sean M Culbertson, Tony Vinson, Antoni Kozlowski, Xiaoming Shen, Mary J Bossard, Hanspeter Rottensteiner, PhD, Barbara Dietrich, DVM, Chyung Cook, Peter L Turecek, PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD, Hans Peter Schwarz, MD, Eva-Maria Muchitsch

Blood (2011) 118 (21): 4358.

https://doi.org/10.1182/blood.V118.21.4358.4358

Published: 2011

Journal Articles

Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model

Pauline M. van Helden, Sabine Unterthurner, Corinna Hermann, Maria Schuster, Rafi U. Ahmad, Alexandra N. Schiviz, Markus Weiller, Gerhard Antoine, Peter L. Turecek, Eva M. Muchitsch, Hans Peter Schwarz, Birgit M. Reipert

Blood (2011) 118 (13): 3698–3707.

https://doi.org/10.1182/blood-2010-11-316521

Published: 2011

Journal Articles

T cell–independent restimulation of FVIII-specific murine memory B cells is facilitated by dendritic cells together with toll-like receptor 7 agonist

Aniko G. Pordes, Christina K. Baumgartner, Peter Allacher, Rafi U. Ahmad, Markus Weiller, Alexandra N. Schiviz, Hans Peter Schwarz, Birgit M. Reipert

Blood (2011) 118 (11): 3154–3162.

https://doi.org/10.1182/blood-2011-02-336198

Published: 2011

Journal Articles

Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9

Peter Allacher, Christina K. Baumgartner, Aniko G. Pordes, Rafi U. Ahmad, Hans Peter Schwarz, Birgit M. Reipert

Blood (2011) 117 (1): 259–267.

https://doi.org/10.1182/blood-2010-06-289009

Published: 2011

Journal Articles

Toxico-Kinetics of Recombinant VWF In Non-Human Primates and Rabbits

Eva-Maria Muchitsch, PhD, Barbara Dietrich, PhD, Hanspeter Rottensteiner, PhD, Herbert Gritsch, Hartmut J. Ehrlich, MD, Peter Turecek, PhD, Hans Peter Schwarz, MD

Blood (2010) 116 (21): 1414.

https://doi.org/10.1182/blood.V116.21.1414.1414

Published: 2010

NARROW

Development of BAX 826, a Polysialylated Full-Length rFVIII with Significantly Improved PK Properties

Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients

Preclinical Safety of Baxter's Recombinant ADAMTS13

Preclinical Efficacy Testing of Baxter's Recombinant ADAMTS13 in a Mouse Model of TTP.

Impact of Factor IXa Content On Function, Safety and Efficacy of Recombinant Factor IX Products.

A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13

CD4 + T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice

Preclinical Immunogenicity Assessment of Baxter‘s Longer-Acting FVIII Candidate BAX 855 Using Novel Preclinical Models,

Preclinical Immunogenicity Assessment of Baxter‘s Recombinant Factor VIIa,

Deciphering of CD4 + T Cell Subsets Involved in Maintenance and Break of Immune Tolerance in a Humanized Mouse Model That Is Immune Tolerant to Human FVII

Induction and Break of Immune Tolerance to Human FVIII in a HLA-DRB1*1501 Humanized Hemophilic Mouse Model

Safety of Baxter’s Longer Acting rFVIII (BAX 855) After Repeated Application in Rats and Cynomolgus Monkeys

Pharmacokinetics of Baxter’s Longer Acting rFVIII (BAX 855) in Factor VIII Ko Mice, Rats and Cynomolgus Monkeys

Efficacy of Baxter’s Longer Acting rFVIII (BAX 855) in Mouse Models of Hemophilia A

Preclinical Safety Pharmacology of Baxter’s Longer Acting rFVIII (BAX 855)

Absorption, Metabolism, Distribution, and Excretion of Longer Acting rFVIII (BAX 855) Following Intravenous Administration to Rats

Maintenance and break of immune tolerance against human factor VIII in a new transgenic hemophilic mouse model

T cell–independent restimulation of FVIII-specific murine memory B cells is facilitated by dendritic cells together with toll-like receptor 7 agonist

Stimulation and inhibition of FVIII-specific memory B-cell responses by CpG-B (ODN 1826), a ligand for Toll-like receptor 9

Toxico-Kinetics of Recombinant VWF In Non-Human Primates and Rabbits

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only